RxSight (RXST) Earnings Date & Reports

Key Takeaways

• RxSight reported third-quarter 2026 revenue of $24.6 million, down 19% from $30.3 million a year earlier and below the roughly $27.2 million consensus estimate.
• Adjusted earnings per share (EPS) came in at a loss of $0.21, narrower than the consensus estimate of a $0.29 loss, driven in part by tighter cost control.
• Light Adjustable Lens (LAL) procedure volume declined 11% year-over-year to 23,128 units, reflecting ongoing competitive pressures in the premium intraocular lens market.
• Gross margin compressed to 73.6% from 79.9% a year ago, weighed down by higher inventory reserves.
• The company ended the quarter with $254.7 million in cash and short-term investments, including a $60 million upfront payment from its Alcon collaboration.
• For more context on RXST's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for deeper data and analysis.
• Explore Trending AI Robots to see how AI-driven trading tools are scanning the market for emerging opportunities.

Earnings Context and Why It Matters

RxSight is a commercial-stage medical technology company focused on the Light Adjustable Lens (LAL), a premium cataract lens that lets physicians fine-tune a patient's vision after surgery using ultraviolet light delivered through the company's Light Delivery Device (LDD). Because the business is still scaling, investors pay close attention to procedure volumes and gross margin trajectory rather than bottom-line profitability alone. The third quarter arrived at a delicate moment: management had already withdrawn full-year 2026 guidance in the prior quarter following a CEO transition, while a new Alcon strategic collaboration and rising competitive activity in the premium intraocular lens (IOL) market reshaped the growth narrative.

Reported Results

For the third quarter of fiscal 2026, RxSight reported total revenue of $24.6 million, a 19% decline from $30.3 million in the year-ago period and below the consensus estimate of roughly $27.2 million. LAL procedure revenue accounted for $22.8 million of the total, while LAL procedure volume fell 11% year-over-year to 23,128 units. Management attributed the softness primarily to ongoing competitive pressures.

On profitability, the company posted a Generally Accepted Accounting Principles (GAAP) net loss of $16.2 million, or $0.39 per basic and diluted share. After adjusting for $7.6 million in stock-based compensation, the non-GAAP net loss was $8.6 million, or $0.21 per share—narrower than the $0.29 adjusted loss Wall Street had expected. Gross margin slipped to 73.6% from 79.9% a year earlier, reflecting an increase in inventory reserves partially offset by a favorable product mix. Selling, general and administrative (SG&A) expenses were $27.4 million, essentially flat year-over-year, while research and development (R&D) spending held steady at $9.2 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking medical device names like RxSight, the AI Screener can help identify comparable opportunities across the healthcare sector with greater speed and precision.

Market Reaction and Investor Sentiment

The market's initial response to the report was negative, with shares trading lower in the after-hours session as the top-line miss outweighed the EPS beat. The revenue shortfall—driven by declining LAL procedure volumes—reinforced concerns that competitive trialing among rival presbyopia-correcting lenses is pressuring demand. Investor sentiment has been cautious for much of 2026, reflecting the withdrawal of full-year guidance, a leadership transition, and an ongoing securities class action. While the company's $254.7 million cash position, bolstered by the Alcon upfront payment, provides financial runway, the near-term reaction underscores that investors are focused on procedure-volume recovery and margin stability rather than cost discipline alone.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central question is whether LAL procedure volumes can stabilize and return to growth. Competition in the premium IOL category remains intense, and investors will want evidence that RxSight's commercial realignment and customer engagement programs are translating into higher utilization across its installed base of Light Delivery Devices.

Gross margin will be another key watch item. The third-quarter decline was driven by inventory reserves, and management has previously flagged that higher-cost inventory manufactured in 2025 could flow through results. Whether margins normalize as production levels stabilize will help determine the company's path toward profitability.

The Alcon collaboration also deserves attention. While the upfront payment strengthened the balance sheet, investors will monitor how the partnership contributes to revenue and whether it accelerates international expansion in Asia and Europe. Finally, with full-year guidance withdrawn, any commentary from the new leadership team about a refreshed strategic direction or reinstated outlook will likely be a significant catalyst for the stock.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations